Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis

Study Region Group N Male/female Age (year) Child-Pugh grade: A/B/C TMN stage: I/II/III/IV Follow-up time (month) Supplementation period (month) Therapy for HCC Study type
Nagasue et al. Japan BCAA 67 54/13 <50:5 50–70:55 > 70:7 53/13/1 24/35/7/1 35.8 ± 17.9 >12 surgery RCT
1998   control 65 55/10 <50:7 50–70:45 > 70:13 50/14/1 22/36/6/1 36.0 ± 17.7    
Meng et al. China BCAA 21 19/2 51.5 ± 10.8 17/4/0 NA 17 (0.2–33) 3 surgery RCT
1999   control 23 18/5 53.3 ± 12.8 20/3/0 NA 17 (2–33)    
Togo et al. Japan BCAA 21 17/4 66.5 ± 4.5 15/7/0 2/14/2/3 12 12 surgery RCT
2005   control 22 17/5 64.3 ± 9.1 17/5/0 3/12/4/3 12    
Okabayashi et al. Japan BCAA 40 29/11 65.7 ± 8.6 33/7/0 NA 16 (2–47) 0.5 surgery cohort
2008   control 72 55/17 68.3 ± 8.1 62/10/0 NA 23 (2–84)    
Ichikawa et al. Japan BCAA 26 18/8 64.7 ± 9.8 21/5/0 NA 40 (7–48) 6.5 surgery RCT
2013   control 30 20/10 64.5 ± 11.4 25/5/0 NA 36 (6–50)    
Kuroda et al. Japan BCAA 20 13/7 65.6 ± 7.0 8/11/1 6/11/3/0 12 12 RFA cohort
2010   control 15 9/6 66.0 ± 8.1 6/8/1 5/8/2/0 12    
Yoshiji et al. Japan BCAA 16 10/6 63.7 ± 10.8 12/4/0 10/5/1/0 48 48 RFA RCT
2011   control 26 16/10 62.5 ± 11.5 21/5/0 18/7/1/0 48    
Nishikawa et al. Japan BCAA 115 64/51 69.3 ± 9.4 83/30/2 41/58/16/0 30 (2–95) >1 RFA cohort
2013   control 141 83/58 70.9 ± 7.8 88/52/1 60/60/21/0 29 (1–84)    
Poon et al. China BCAA 41 39/2 59 (24–84) NA 30/11/0/0 29 (18–44 ) 12.5 TACE RCT
2004   control 43 39/4 59 (27–80) NA 31/12/0/0 30 (18–43)    
Kanekawa et al. Japan BCAA 49 43/6 66.3 ± 7.0 23/26/0 0/0/41/8 NA NA HAIC cohort
2014   control 43 34/9 68.0 ± 7.0 30/13/0 0/0/29/14 NA    
Takeda et al. Japan BCAA 33 27/7 72 (55–88) 16/18/0 0/2/15/17 NA NA sorafenib cohort
2014   control 44 37/7 68 (46–89) 30/14/0 0/2/11/31 NA    
  1. RFA radiofrequency ablation, TACE, transarterial chemoembolization, HAIC, hepatic arterial infusion chemotherapy; RCT, randomized controlled trial, NA, not available